DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialGuruFocus · 2 days ago
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialBusiness Wire · 2 days ago
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader WebinarBusiness Wire · 5 days ago
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR ResultsBusiness Wire · Sep 30, 2026
DiaMedica Therapeutics to Participate in Upcoming September Investor ConferencesGuruFocus · Sep 2, 2026
DiaMedica Therapeutics to Participate in Upcoming September Investor ConferencesBusiness Wire · Sep 2, 2026DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.20 | -$0.19 | Beat |
| May 6, 2026 | -$0.17 | -$0.19 | Miss |
| Mar 30, 2026 | -$0.17 | -$0.17 | Beat |
| Nov 12, 2025 | -$0.15 | -$0.17 | Miss |
| Aug 12, 2025 | -$0.18 | -$0.18 | Beat |
| May 13, 2025 | -$0.18 | -$0.18 | Beat |